Detalhe da pesquisa
1.
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.
Nature
; 477(7362): 99-102, 2011 Aug 31.
Artigo
Inglês
| MEDLINE | ID: mdl-21886163
2.
Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers.
Mol Ther
; 24(8): 1492-501, 2016 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-27203445
3.
Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
Mol Ther
; 23(9): 1532-40, 2015 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-26073886
4.
First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.
Mol Ther
; 23(1): 202-14, 2015 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-25292189
5.
Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.
Mol Ther
; 23(3): 602-8, 2015 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-25531693
6.
Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.
Mol Ther
; 23(6): 1066-1076, 2015 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-25807289
7.
Translational control of the innate immune response through IRF-7.
Nature
; 452(7185): 323-8, 2008 Mar 20.
Artigo
Inglês
| MEDLINE | ID: mdl-18272964
8.
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.
Mol Ther
; 20(4): 749-58, 2012 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-22186794
9.
A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.
Mol Ther
; 19(10): 1913-22, 2011 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-21772252
10.
Targeting tumor vasculature with an oncolytic virus.
Mol Ther
; 19(5): 886-94, 2011 May.
Artigo
Inglês
| MEDLINE | ID: mdl-21364541
11.
Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.
Mol Ther
; 19(6): 1170-9, 2011 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-21427706
12.
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
Front Immunol
; 13: 1029269, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36405739
13.
Considerations for Clinical Translation of MG1 Maraba Virus.
Methods Mol Biol
; 2058: 285-293, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-31486046
14.
Efficacy of systemically administered mutant vesicular stomatitis virus (VSVDelta51) combined with radiation for nasopharyngeal carcinoma.
Clin Cancer Res
; 14(15): 4891-7, 2008 Aug 01.
Artigo
Inglês
| MEDLINE | ID: mdl-18676763
15.
Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.
Oncoimmunology
; 8(1): e1512329, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-30546947
16.
Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?
Curr Opin Mol Ther
; 10(1): 32-7, 2008 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-18228179
17.
Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms.
Cancer Res
; 78(4): 922-937, 2018 02 15.
Artigo
Inglês
| MEDLINE | ID: mdl-29259007
18.
Development and applications of oncolytic Maraba virus vaccines.
Oncolytic Virother
; 7: 117-128, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-30538968
19.
Oncolytic Viruses: Therapeutics With an Identity Crisis.
EBioMedicine
; 9: 31-36, 2016 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-27407036
20.
Oncolytic viruses: perspectives on clinical development.
Curr Opin Virol
; 13: 55-60, 2015 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-25989094